Results 211 to 220 of about 354,007 (274)

Safety of leukotriene receptor antagonists in pregnancy

Journal of Allergy and Clinical Immunology, 2007
Asthma is a chronic disorder that affects about 8% of pregnant women and may complicate pregnancy. Adequate asthma therapy in pregnancy is crucial but challenging because of safety concerns for the fetus.To evaluate the safety of gestational asthma therapy with leukotriene receptor antagonists (LTRAs) for the mother and fetus/newborn.Subjects were ...
Ludmila N, Bakhireva, Kenneth Lyons, Jones, Michael, Schatz, Hillary S, Klonoff-Cohen, Diana, Johnson, Donald J, Slymen, Christina D, Chambers   +6 more
openaire   +2 more sources

Leukotriene receptor antagonists in asthma therapy

Journal of Allergy and Clinical Immunology, 2003
In persons with asthma, the cysteinyl leukotrienes possess multiple inflammatory properties in vitro and have long been considered to be a potentially important mediator of asthma and an attractive target for therapeutic intervention. Controlled clinical trials have documented the efficacy of leukotriene receptor antagonists in asthma treatment, but ...
Peters, Stephen P., Hamid, Qutayba, Moqbel, Redwan, Sampson, Anthony, Peters-Golden, Marc, Leff, Jon, Pizzichini, Emilio, Edelman, Jon, Liu, Mark, Bisgaard, Hans, Henderson, Bill   +10 more
openaire   +3 more sources

Leukotriene Receptor Antagonists and Antiallergy Drugs

2016
As one of the candidates of the therapeutic strategy for asthma in addition to inhaled corticosteroids (ICS), leukotriene receptor antagonists (LTRAs) are known to be useful for long-term management of asthma patients complicated by allergic rhinitis (AR) or exercise-induced asthma (EIA).
Tsutomu, Tamada, Masakazu, Ichinose
openaire   +2 more sources

[Leukotriene receptor antagonists].

Bioorganicheskaia khimiia, 1993
The review covers the aspects of classification, specificity and structure--biological activity relations in leukotriene receptor antagonists which blockade the action of the acyclic arachidonate metabolites. Prospects of designing new medicines based on these compounds are also discussed.
D M, Kochev, R S, Vorisova, D A, Zabolotskiĭ, G I, Miagkova   +3 more
openaire   +1 more source

Leukotriene Receptor Antagonists in the Treatment of Asthma

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2001
The role of leukotriene receptor antagonists in the treatment of persistent asthma is in evolution. Pivotal 8–12‐week, randomized, controlled trials in both adults and children have shown efficacy, as defined by standard asthma outcomes. Tolerance to therapy did not develop, nor did rebound worsening of asthma symptoms once therapy was withdrawn.
openaire   +2 more sources

Effects of cysteinyl leukotrienes and leukotriene receptor antagonists on markers of inflammation

Journal of Allergy and Clinical Immunology, 2003
The understanding that asthma pathophysiology includes an inflammatory component has spurred the more aggressive use of anti-inflammatory therapies and created a need for effective tools to measure inflammation. Biomarkers of airway inflammation proposed are obtained by methods that are direct but highly invasive (bronchial biopsy, bronchoalveolar ...
Sampson, Anthony P., Pizzichini, Emilio, Bisgaard, Hans   +2 more
openaire   +3 more sources

Leukotriene Receptor Antagonists as Potential Therapeutic Agents

Annual Review of Pharmacology and Toxicology, 1989
Leukotrienes are a family of bioactive lipids that have a constellation of pharmacologic effects on respiratory, cardiovascular, and gastrointestinal systems. They produce smooth muscle spasm (1, 2), cause myocardial de­ pression (3), increase vascular permeability ( l , 4) enhance mucous produc­ tion (5), decrease mucociliary transport (6), and have ...
D W, Snyder, J H, Fleisch
openaire   +2 more sources

Challenge Studies of a Leukotriene Receptor Antagonist

Chest, 1997
The leukotriene receptor antagonist pranlukast (SB 205312, ONO-1078) has demonstrated clinical activity as an antiasthma drug in traditional challenge models, including exercise-induced asthma and inhaled bronchoprovocations with sulpyrine (an aspirin analogue), antigen, methacholine, leukotriene C4, and leukotriene D4. This article reviews the results
openaire   +2 more sources

Leukotriene receptor antagonists in the treatment of asthma: an update

Allergy, 2002
Leukotriene receptor antagonists (LTRAs), such as montelukast and zafirlukast, have been demonstrated in a number of studies to possess bronchodilating and anti‐inflammatory properties, that make these drugs ideal candidates for the treatment of asthma. The last 1998‐updating of the GINA Guidelines for the diagnosis and therapy of asthma recommends the
G, Balzano, S, Fuschillo, C, Gaudiosi
openaire   +2 more sources

Leukotriene Receptor Antagonists

2022
Rui Zheng, Tian Yuan, Qintai Yang
openaire   +1 more source